Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as general partner, has made an additional investment in Phimex Corporation ("Phimex"), a venture company utilizing Kyoto University's research results. ("Phimex") (Head office: Fujisawa City, Kanagawa Prefecture; Representative Director: Yusuke Tominari), a venture company that utilizes research results from Kyoto University.

Phimex is a drug discovery venture that is engaged in the research and development of novel drugs that use proteolysis induction as their mechanism of action, which has attracted worldwide attention in recent years. Using RaPPIDS™, the company is conducting research and development of its own pipeline and collaborative research with leading research institutions in Japan and overseas, including Kyoto University (Associate Professor Kim Hyeon-hyuk, Graduate School of Medicine).

With this funding, the company plans to advance the preclinical safety studies of the IRAK-M proteolysis inducer, its internal lead program, and to accelerate research on the proteolysis inducers of both TRIB1 and ILK proteins, a follow-on program. In addition, the platform technology RaPPIDSTMWe will further improve and develop the technology into a technology that can be offered not only to our own programs but also to pharmaceutical companies.

Kyoto iCAP is the result of Phimex's advanced technology for creating targeted proteolysis inducers and RaPPIDSTMThe decision to make this additional investment was based on the company's policy of contributing to people's health through its products and services. The total amount of 1.175 billion yen raised by Phimex in the Series B private placement was 200 million yen, which was subscribed by Nissay Capital Corporation (headquartered in Chiyoda-ku, Tokyo; Tetsuya Adachi, Representative Director), ANRI Corporation (headquartered in Shibuya-ku, Tokyo; Anri Samata, Representative Director), and University of Tokyo Collaborative Platform Development Corporation (headquartered in Bunkyo-ku, Tokyo; Katsuhiko Oizumi, Representative Director), along with Phimex. (Head office: Bunkyo-ku, Tokyo; Representative Director: Katsuhiko Oizumi), and subscribed 200 million yen.

0 Phimex Corporation
Phimex is a drug discovery venture company that conducts research and development of novel drugs with proteolysis as their mechanism of action. Based on its proprietary E3 ligase-binding molecule and its drug discovery platform technology, RaPPIDS™, Phimex is pursuing multiple first-in-class drug development programs targeting proteins related to cancer diseases, which have been considered "undruggable". We are currently pursuing several first-in-class drug development programs targeting cancer-related proteins that have been considered "undruggable". By utilizing RaPPIDS™ not only for internal projects but also for collaborative research with domestic and international companies and research institutions, we will address a wide range of drug targets and unmet medical needs to provide life-saving medicine for patients and families worldwide.
uniform resouce locator https://www.fimecs.com/

Established January 2018
Business Description Research and development of novel pharmaceuticals with proteolysis-inducing mechanisms
Head Office Fujisawa City, Kanagawa Prefecture
Representative Director Yusuke Tominari
Contact E-mail:info@fimecs.com
　　　　　　Tel: 0466-96-0261